Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios Dimopoulos

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Haematologica|July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydePellegrino Musto, Monika Engelhardt, Jo Caers, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Haematologica|January 26, 2006
Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic diseaseTheodoros P Vassilakopoulos, Maria K Angelopoulou, Marina P Siakantaris, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
American Journal of Hematology|June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.
Leukemia|May 24, 2018
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsNiccolo Bolli, Giulia Biancon, Matahi Moarii, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional StudyMohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Haematologica|July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydePellegrino Musto, Monika Engelhardt, Jo Caers, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Haematologica|January 26, 2006
Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic diseaseTheodoros P Vassilakopoulos, Maria K Angelopoulou, Marina P Siakantaris, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
American Journal of Hematology|June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.
Leukemia|May 24, 2018
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsNiccolo Bolli, Giulia Biancon, Matahi Moarii, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional StudyMohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
Pageof 12